{
  "docId": "019de070-7de1-7343-8d2f-5d51a9877c50",
  "docSlug": "ff3158b4501b6094038126272ca46097",
  "documentTitle": "BioAtla | IPO Presentation Deck | 31 slides",
  "authorId": "bioatla",
  "authorName": "BioAtla",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2020-12-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 12,
  "pageCount": 31,
  "prevPage": 11,
  "nextPage": 13,
  "slideType": "traction",
  "function": "show_traction",
  "density": "dense",
  "nDataPoints": 6,
  "notes": "Includes specific clinical trial metrics and radiological evidence of efficacy.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de070-7de1-7343-8d2f-5d51a9877c50/12",
  "deckHref": "/decks/019de070-7de1-7343-8d2f-5d51a9877c50",
  "deckJsonHref": "/decks/019de070-7de1-7343-8d2f-5d51a9877c50.json",
  "deckAnchorHref": "/decks/019de070-7de1-7343-8d2f-5d51a9877c50#slide-12",
  "components": [
    {
      "bbox": {
        "h": 0.45,
        "w": 0.55,
        "x": 0.05,
        "y": 0.2
      },
      "kind": "chart",
      "text": "Waterfall plot showing maximum % change from baseline in target lesions for various sarcoma subtypes.",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "679af760-b0cb-46c4-860b-32de49546d5a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.6,
        "x": 0.05,
        "y": 0.85
      },
      "kind": "disclaimer",
      "text": "Note: **AXL Tumor membrane Percent Score or TmPS = % Score ≥1+; †Tissue biopsy from resection, over 1 year old prior to trial entry; All patients: Multiple cycles of antineoplastic agents received prior to starting treatment with BA3011; ¹NED = No evidence of disease",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "057dddce-74dd-4c07-bc77-8391bb60689e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.7,
        "w": 0.3,
        "x": 0.65,
        "y": 0.15
      },
      "kind": "image",
      "text": "Pre-treatment and Post-treatment CT scans showing tumor reduction.",
      "attrs": null,
      "subkind": "screenshot",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5e1bbc27-01f8-44ed-b614-125d7a59b292",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.28,
        "x": 0.35,
        "y": 0.7
      },
      "kind": "metric",
      "text": "4 partial responses out of 6 for sarcoma patients with TmPS ≥70 at the optimal dosing levels",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ac56d461-f046-435a-8007-d90633e7dd97",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.28,
        "x": 0.05,
        "y": 0.7
      },
      "kind": "metric",
      "text": "Out of 61 sarcoma patients screened for AXL Tumor Membrane Expression: 35 had a TmPS ≥ 70 (57%)",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f4ba6959-ccee-4392-b45e-ce72e43a9fe6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.8,
        "x": 0.05,
        "y": 0.02
      },
      "kind": "title",
      "text": "BA3011: Encouraging Results in AXL High (TmPS ≥70) Sarcoma Patients at 1.8mg/kg",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "22795b75-9cdf-4646-a067-df7507e091ae",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Waterfall chart",
      "slug": "waterfall-chart",
      "agent": null,
      "layer": "slide",
      "matchId": "9f485bd9-e6c2-4577-86df-ea264381c2a5",
      "evidence": "chart/bar-vertical: Waterfall plot showing maximum % change from baseline in target lesions for various sarcoma subtypes.",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 21,
      "from": 12,
      "beatId": "2003e560-8567-434b-89b9-686dbf1d7731",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Traction",
      "beatSlug": null,
      "evidence": "The document presents traction information on pages 12-21.",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [
    {
      "to": 15,
      "from": 11,
      "name": "Why Now",
      "slug": "15-why-now",
      "bestFor": "Sales pitches, fundraising, requesting immediate budget approval",
      "matchId": "e68a7a0d-6e24-461d-8cb2-101d25fdd683",
      "evidence": "The document presents information on the current market opportunity and the company's progress on pages 11-15.",
      "position": 1,
      "objective": "Why is now the right time to invest in BioAtla?",
      "structure": "The Context (Trends) -> The Trigger Event -> The Window of Opportunity",
      "confidence": 0.6,
      "description": "Create temporal urgency by proving that the window of opportunity is opening or closing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}